Patheon Announces Launch of Updated Quick to Clinic™ Program

Patheon, the pharmaceutical services business owned by DPx Holdings B.V., announced the launch of its updated program Quick to Clinic™, making it the only CDMO to offer customers an accelerated 12-week clinical trial material program with stability data with a variety of flexible dosage forms.

The Quick to Clinic™ offering includes a month of clinical trial stability studies, provides customers access to six flexible dosage forms and decreases the wait time from receipt of API for clinical trial materials for First in Human trials by one month. Patheon customers can now receive high-quality Phase I clinical trial materials in as few as 12 weeks and with stability data, delivering maximum speed without compromising quality.

The six Quick to Clinic™ dosage forms offered by Patheon include blend in capsule, API in capsule, blend in bottle, API in bottle, oral liquid and softgel.

With expansive resources and expertise, Quick to Clinic™ offers customers the ability to meet their unique scientific requirements with capabilities spanning from formulation development and manufacturing to clinical packaging and distribution.

“We are excited about the enhanced Quick to Clinic program and the benefit that it will provide to our  customers,” says Mike Lehmann, President, PDS and Executive Vice President, Global Sales and Marketing, Patheon. “We are now the only CDMO that can offer customers a 12-week clinical trial program that delivers maximum speed, but does not compromise quality.”

Quick to Clinic™ was first launched in 2009, and Patheon has refreshed the program and expanded it to include its sites in Cincinnati, Ohio; Milton Park, U.K.; Tilburg, the Netherlands; and Toronto, Ontario. 


Tel: +1 (919) 226-3200


About Patheon

Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPx Holdings B.V. business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business. For more information visit